ACAD
40.55
+0.33
+0.82%
AEMD
8.75
-0.1
-1.13%
APRI
1.56
+0.06
+4.00%
ARNA
4.19
-0.01
-0.24%
ATEC
1.36
+0.01
+0.74%
CNAT
5.36
+0.04
+0.75%
CRXM
0.5
0.00
0.00%
CYTX
0.66
-0.021
-3.0548%
DXCM
68.68
+0.43
+0.63%
GNMK
9.04
+0.01
+0.11%
HALO
17.45
+0.2
+1.16%
ILMN
205
+1.88
+0.93%
INNV
0.153
+0.003
+1.6667%
INO
8.83
+0.57
+6.90%
ISCO
0.05
0.00
0.00%
ISIS
67.76
+0.59
+0.88%
LGND
89.67
+0.44
+0.49%
LPTN
0.305
+0.008
+2.6599%
MBVX
2.29
-0.09
-3.78%
MEIP
1.87
-0.04
-2.09%
MNOV
4.05
+0.05
+1.25%
MRTX
26.81
+0.97
+3.75%
MSTX
0.49
-0.01
-2.97%
NBIX
42.55
+0.57
+1.36%
NUVA
48.25
+0.02
+0.04%
ONCS
0.233
0.00
0.00%
ONVO
4.65
-0.03
-0.64%
OREX
5.01
+0.01
+0.20%
OTIC
24.86
-6.19
-19.94%
QDEL
21.84
-0.89
-3.92%
RCPT
161.65
+1.54
+0.96%
RGLS
12.85
+0.1
+0.78%
RMD
57.08
-0.24
-0.42%
SCIE
0.02
+0.005
+30.2632%
SPHS
0.845
-0.014
-1.630%
SRNE
12.94
-0.27
-2.04%
TROV
10.93
+0.64
+6.22%
VICL
0.926
+0.036
+4.045%
VOLC
17.99
0.00
0.00%
ZGNX
1.4
0.00
0.00%
ACAD
40.55
+0.33
+0.82%
AEMD
8.75
-0.1
-1.13%
APRI
1.56
+0.06
+4.00%
ARNA
4.19
-0.01
-0.24%
ATEC
1.36
+0.01
+0.74%
CNAT
5.36
+0.04
+0.75%
CRXM
0.5
0.00
0.00%
CYTX
0.66
-0.021
-3.0548%
DXCM
68.68
+0.43
+0.63%
GNMK
9.04
+0.01
+0.11%
HALO
17.45
+0.2
+1.16%
ILMN
205
+1.88
+0.93%
INNV
0.153
+0.003
+1.6667%
INO
8.83
+0.57
+6.90%
ISCO
0.05
0.00
0.00%
ISIS
67.76
+0.59
+0.88%
LGND
89.67
+0.44
+0.49%
LPTN
0.305
+0.008
+2.6599%
MBVX
2.29
-0.09
-3.78%
MEIP
1.87
-0.04
-2.09%
MNOV
4.05
+0.05
+1.25%
MRTX
26.81
+0.97
+3.75%
MSTX
0.49
-0.01
-2.97%
NBIX
42.55
+0.57
+1.36%
NUVA
48.25
+0.02
+0.04%
ONCS
0.233
0.00
0.00%
ONVO
4.65
-0.03
-0.64%
OREX
5.01
+0.01
+0.20%
OTIC
24.86
-6.19
-19.94%
QDEL
21.84
-0.89
-3.92%
RCPT
161.65
+1.54
+0.96%
RGLS
12.85
+0.1
+0.78%
RMD
57.08
-0.24
-0.42%
SCIE
0.02
+0.005
+30.2632%
SPHS
0.845
-0.014
-1.630%
SRNE
12.94
-0.27
-2.04%
TROV
10.93
+0.64
+6.22%
VICL
0.926
+0.036
+4.045%
VOLC
17.99
0.00
0.00%
ZGNX
1.4
0.00
0.00%
Home » Archive by Category

Syndication

Project Manager – Immunodiagnostics

May 20, 2015 – 4:30 am

CA-Carlsbad, Project Manager, Immunodiagnostics, Carlsbad, CA Kelly Scientific Resources, a division of Kelly Services, is currently seeking a Project Manager, Immunodiagnostics with a growing company located in Carlsbad, CA. Job Description: Responsib…

OncoSec Medical to Present Data at the New York Academy of Sciences’ Cancer Immunotherapy Symposium

May 20, 2015 – 3:00 am

SAN DIEGO, May 20, 2015 /PRNewswire/ — OncoSec Medical Inc. (“OncoSec”) (OTCQB: ONCSD), a company developing DNA-based intratumoral cancer immunotherapies, will present data from ongoing clinical and preclinical studies at the New York Academy of Sciences’ Emerging Approaches to Cancer Immunotherapy. OncoSec’s Chief Scientific Officer Robert H. Pierce, MD, and Chief Medical Officer Mai. H. Le, MD, will present an abstract entitled: “Intratumoral Expression of Plasmid IL-12 Can Increase CD8 TILs and Drive Systemic Anti-Tumor Responses: Rationale for Combination with Anti-PD-1 Blockade” as part of a poster presentation beginning at 12:10 PM ET on Thursday, May 21, 2015 in New York City.

The poster presentation will discuss the unmet medical need of “anti-PD-1 non-responders,” which are characterized by the absence of immune cells, and the role of interventions that are specifically focused on increasing tumor-infiltrating lymphocytes (TILs). By increasing TILs and promoting tumor immunogenicity, these interventions may convert anti-PD-1 non-responders to responders. Intratumoral electroporation-mediated gene therapy with DNA-based IL-12 has demonstrated single-agent anti-tumor efficacy in both preclinical tumor models as well as Phase I and II clinical trials in advanced melanoma. The data highlighted in this presentation suggest that intratumoral delivery of DNA-based IL-12 followed by electroporation can increase CD8 TILs, promote tumor immunogenicity, drive systemic anti-tumor responses, and increase the patient population who may benefit from therapeutic PD-1/PD-L1 blockade.

Abstract information is as follows:

  • Title: Intratumoral Expression of Plasmid IL-12 Can Increase CD8 TILs and Drive Systemic Anti-Tumor Responses: Rationale for Combination with Anti-PD-1 Blockade
  • Presenters: Robert H. Pierce, MD; Mai. H. Le, MD
  • Time/Date: 12:10 PM ET, Thursday, May 21, 2015
  • Location: The New York Academy of Sciences

About Emerging Approaches to Cancer Immunotherapy
Emerging Approaches to Cancer Immunotherapy is hosted by the New York Academy of Sciences to bring together leading experts in immunotherapy and immunology to discuss emerging approaches, along with the challenges and opportunities faced in this evolving field. Over the past several years, cancer immunotherapy has made progress both conceptually and in clinical practice. Led by landmark studies in the setting of metastatic melanoma, many of the findings of this field are being generalized both to hematological malignancies and to other solid tumors. Areas of investigation such as checkpoint blockade inhibitors, advanced tumor vaccination studies, and adoptive T-cell therapies are changing the face of cancer treatment, and will be discussed at the upcoming meeting. For more information, please visit: www.nyas.org

About OncoSec Medical Inc.
OncoSec Medical Inc. is a biopharmaceutical company developing its investigational ImmunoPulse™ intratumoral cancer immunotherapy. OncoSec’s core technology is designed to enhance the local delivery and uptake of DNA IL-12 and other DNA-based immune-targeting agents. Clinical studies of ImmunoPulse™ have demonstrated an acceptable safety profile and preliminary evidence of anti-tumor activity in the treatment of various skin cancers, as well as the potential to initiate a systemic immune response limiting the systemic toxicities associated with other treatments. OncoSec’s lead program evaluating ImmunoPulse™ for the treatment of metastatic melanoma is currently in Phase II development, and is being conducted in collaboration with several prominent academic medical centers. As the company continues to evaluate ImmunoPulse™ in its current indications, it is also focused on identifying and developing new immune-targeting agents, investigating additional tumor indications, and evaluating combination-based immunotherapy approaches. For more information, please visit www.oncosec.com.

OncoSec Medical Inc. Forward Looking Statements
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such “forward-looking statements.” Forward-looking statements are based on management’s current preliminary expectations and are subject to risks and uncertainties, which may cause our results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition, and market conditions. These and additional risks and uncertainties are more fully described in OncoSec Medical’s filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. OncoSec Medical disclaims any obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

CONTACT:
Investor Relations:
Jordyn Kopin
OncoSec Medical Inc.
855-662-6732
investors@oncosec.com 

Media Relations:
Mary Marolla
OncoSec Medical Inc.
855-662-6732
media@oncosec.com 

Logo – http://photos.prnewswire.com/prnh/20120905/LA68078LOGO

 

SOURCE OncoSec Medical Inc.

Project Coordinator – Biotech – Sequoia – San Diego, CA

May 20, 2015 – 2:09 am

Provides effective data collection and dissemination to the Project Manager and Teams, ensuring project deliverables are met….
From Sequoia – 23 May 2015 03:07:24 GMT
– View all San Diego jobs

Clinical Documentation Manager (Archivist) – Intercept Pharmaceuticals – San Diego, CA

May 20, 2015 – 12:38 am

Minimum of 5-6+ years pharmaceutical, biotechnology or CRO clinical research experience. The Clinical Documentation Manager (Archivist) is responsible for the…
From Intercept Pharmaceuticals – 20 May 2015 07:38:57 GMT
– View …

Collection Representative (Biotech) at Simply Biotech (San Diego, CA)

May 19, 2015 – 9:21 pm

Collection Representative (Biotech) Simply Biotech is currently seeking a Collection Representative for a leading and growing device firm in San Diego CA. In this role, you will ensure timely collection of outstanding A/R and perform a…

Clinical Research Scientist at Simply Biotech (San Diego, CA)

May 19, 2015 – 9:21 pm

or call 858.487.0507. FULL DESCRIPTION: Simply Biotech specializes in recruiting exclusively for the biotech community. … Research Scientist for a leading and growing biotech firm. The Clinical Research Scientist will be responsible for…

Electrical Engineer III at Simply Biotech (San Diego, CA)

May 19, 2015 – 9:21 pm

Electrical Engineer III Defense Search specializes in recruiting exclusively for the defense and aerospace industries. We are currently seeking an Electrical Engineer III for a leading Defense company. This position is based in San Diego,…

Program Manager

May 19, 2015 – 9:00 pm

Details: Program Manager needed for a contract opportunity with Yoh’s client located in Warsaw, IN . The Big Picture – Top Skills Should You Possess: Product development Brand management Medical device environment What You’ll Be Doing: Provide new product management expertise that will enable the business to identify, develop and commercialize quality products. Optimizing the project and portfolio management methodologies via training and coaching, the development of and maintenance of new tools and processes and sharing best practices across functions and divisions. Be the process expert by being responsible for incorporating, supporting, training and improving FOCUS methodologies. Be the process expert for portfolio management by incorporating and supporting processes and tools that are used to identify, prioritize and select opportunities / projects for optimal portfolio value and strategic alignment. Monitor NPD activity and provides management monthly updates on the status of projects via a report or online dashboard. Assist core team leaders in the optimal management of their core teams by providing the necessary FOCUS training and facilitating team activities for team-building, planning, decision-making and problem-solving. Lead the development of core team members and core team leaders by sponsoring or providing necessary training for the further development of their project management and leadership skills. Collect and analyze the performance of the new product development effort by collecting data for key metrics and reporting out the performance. Schedule, manage, document, and be an active participant in the phase reviews for Recon to ensure the appropriate use of the FOCUS process and the timely development and commercialization of new products. Lead selected core teams as directed by the business GM. What You Need to Bring to the Table: Bachelor’s degree in an analytical field or related science required Minimum five (5) years experience in new product development required Experience working in a medical device regulated environment Experience working in a matrix organization Experience managing a functional area within brand management, product development, finance or operations is preferred, with demonstrated results-oriented performance Certified Project Manager Professional (PMP) is preferred Broad knowledge of new product development methodologies and tools Demonstrated ability to lead and coach the implementation of NPD process improvements through cross-functional teams by listening and utilizing influence skills Able to take action in solving problems and making decisions while exhibiting judgment and a realistic understanding of issues, able to use reason, even when dealing with emotional topics Must possess an established track record of sound cross-functional actions and decisions impacting the business process and company results Demonstrated ability to communicate effectively (both oral and written) in a clear and concise manner Able to clearly present information, influence or persuade others through oral presentations in positive and negative circumstances, listens well Must be able emit a level of confidence and expertise to effectively train other employees at multiple sites in a broad range of NPD topics What’s In It For You? This is your opportunity to lead a team in the roll-out of a new product within a well established medical device company! Opportunity is Calling, Apply Now! Recruiter: Jerome Adams Yoh makes finding and applying for jobs simple. Partner with Yoh to find the right opportunities across multiple industries in the US and UK. Find out more here ! Yoh, a Day & Zimmermann company, is an Equal Opportunity Employer, M/F/D/V. Click here to contact us if you are an individual with a disability and require accommodation in the application process. J2W: PROF MONJOB CB1

Project Manager – Ajinomoto Althea, Inc. – San Diego, CA

May 19, 2015 – 5:33 pm

Under general supervision this position drives planning, decision-making, develops implementation strategies and lead efforts for projects….
From Ajinomoto Althea, Inc. – 20 May 2015 00:33:46 GMT
– View all San Diego jobs

Gel Filled With Nanosponges Cleans Up MRSA Infections, University of California, San Diego (UCSD) Study

May 19, 2015 – 5:00 pm

Gel Filled With Nanosponges Cleans Up MRSA Infections Nanoengineers at the University of California, San Diego developed a gel filled with toxin-absorbing nanosponges that could lead to an effective treatment for skin and wound infections caused by MR…